Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma

Figure 1 Flowchart of study selection.

Figure 2 Forest plots of survival outcomes. A: The pooled effect size of median progression-free survival; B: The pooled effect size of median over survival.

Figure 3 Forest plots of tumor responses. A: The pooled complete response rate; B: The pooled objective response rate; C: The pooled disease control rate.

Figure 4 Forest plots of adverse events. A: The pooled rate of all-grade adverse events (AEs); B: The pooled rate of grade ≥ 3 AEs.